Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 2.00
DHRM's Cash to Debt is ranked higher than
70% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.07 vs. DHRM: 2.00 )
DHRM' s 10-Year Cash to Debt Range
Min: 0.19   Max: 3.91
Current: 2

0.19
3.91
Equity to Asset 0.85
DHRM's Equity to Asset is ranked higher than
90% of the 375 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. DHRM: 0.85 )
DHRM' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.85
Current: 0.85

0.51
0.85
Interest Coverage 22.04
DHRM's Interest Coverage is ranked higher than
58% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 155.63 vs. DHRM: 22.04 )
DHRM' s 10-Year Interest Coverage Range
Min: 15.42   Max: 73.27
Current: 22.04

15.42
73.27
F-Score: 4
Z-Score: 4.30
M-Score: -2.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 20.79
DHRM's Operating margin (%) is ranked higher than
93% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 6.58 vs. DHRM: 20.79 )
DHRM' s 10-Year Operating margin (%) Range
Min: 15.89   Max: 27.09
Current: 20.79

15.89
27.09
Net-margin (%) 11.83
DHRM's Net-margin (%) is ranked higher than
92% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 5.13 vs. DHRM: 11.83 )
DHRM' s 10-Year Net-margin (%) Range
Min: 9.75   Max: 23.17
Current: 11.83

9.75
23.17
ROE (%) 5.80
DHRM's ROE (%) is ranked higher than
80% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 5.99 vs. DHRM: 5.80 )
DHRM' s 10-Year ROE (%) Range
Min: 5.83   Max: 33.66
Current: 5.8

5.83
33.66
ROA (%) 4.91
DHRM's ROA (%) is ranked higher than
85% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 3.76 vs. DHRM: 4.91 )
DHRM' s 10-Year ROA (%) Range
Min: 4.96   Max: 17.35
Current: 4.91

4.96
17.35
ROC (Joel Greenblatt) (%) 11.30
DHRM's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 12.84 vs. DHRM: 11.30 )
DHRM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 11.51   Max: 61.75
Current: 11.3

11.51
61.75
Revenue Growth (%) -8.50
DHRM's Revenue Growth (%) is ranked higher than
54% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. DHRM: -8.50 )
DHRM' s 10-Year Revenue Growth (%) Range
Min: -8.5   Max: 15.1
Current: -8.5

-8.5
15.1
EBITDA Growth (%) -20.40
DHRM's EBITDA Growth (%) is ranked higher than
61% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -2.20 vs. DHRM: -20.40 )
DHRM' s 10-Year EBITDA Growth (%) Range
Min: -20.4   Max: 18.3
Current: -20.4

-20.4
18.3
EPS Growth (%) -26.70
DHRM's EPS Growth (%) is ranked higher than
56% of the 271 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. DHRM: -26.70 )
DHRM' s 10-Year EPS Growth (%) Range
Min: -26.7   Max: 30.6
Current: -26.7

-26.7
30.6
» DHRM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with DHRM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 12.20
DHRM's P/E(ttm) is ranked higher than
98% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 60.80 vs. DHRM: 12.20 )
DHRM' s 10-Year P/E(ttm) Range
Min: 1.52   Max: 24.05
Current: 12.2

1.52
24.05
P/B 0.70
DHRM's P/B is ranked higher than
98% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.46 vs. DHRM: 0.70 )
DHRM' s 10-Year P/B Range
Min: 0.22   Max: 1.35
Current: 0.7

0.22
1.35
P/S 1.40
DHRM's P/S is ranked lower than
56% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. DHRM: 1.40 )
DHRM' s 10-Year P/S Range
Min: 0.29   Max: 2.86
Current: 1.4

0.29
2.86
EV-to-EBIT 6.33
DHRM's EV-to-EBIT is ranked higher than
56% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 38.19 vs. DHRM: 6.33 )
DHRM' s 10-Year EV-to-EBIT Range
Min: 0.7   Max: 13.6
Current: 6.33

0.7
13.6
Current Ratio 9.57
DHRM's Current Ratio is ranked higher than
95% of the 393 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. DHRM: 9.57 )
DHRM' s 10-Year Current Ratio Range
Min: 1.96   Max: 9.57
Current: 9.57

1.96
9.57
Quick Ratio 8.28
DHRM's Quick Ratio is ranked higher than
95% of the 393 Companies
in the Global Medical Devices industry.

( Industry Median: 2.07 vs. DHRM: 8.28 )
DHRM' s 10-Year Quick Ratio Range
Min: 1.66   Max: 8.28
Current: 8.28

1.66
8.28

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 2.30
DHRM's Price/Net Current Asset Value is ranked higher than
99% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. DHRM: 2.30 )
DHRM' s 10-Year Price/Net Current Asset Value Range
Min: 0.56   Max: 7.62
Current: 2.3

0.56
7.62
Price/Tangible Book 0.70
DHRM's Price/Tangible Book is ranked higher than
98% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. DHRM: 0.70 )
DHRM' s 10-Year Price/Tangible Book Range
Min: 0.22   Max: 1.09
Current: 0.7

0.22
1.09
Price/Median PS Value 2.90
DHRM's Price/Median PS Value is ranked higher than
51% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 1.19 vs. DHRM: 2.90 )
DHRM' s 10-Year Price/Median PS Value Range
Min: 0.59   Max: 2.52
Current: 2.9

0.59
2.52
Price/Graham Number 0.60
DHRM's Price/Graham Number is ranked higher than
99% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 6.52 vs. DHRM: 0.60 )
DHRM' s 10-Year Price/Graham Number Range
Min: 0.14   Max: 0.53
Current: 0.6

0.14
0.53
Earnings Yield (Greenblatt) 14.90
DHRM's Earnings Yield (Greenblatt) is ranked higher than
94% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. DHRM: 14.90 )
DHRM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 7.4   Max: 134.5
Current: 14.9

7.4
134.5
Forward Rate of Return (Yacktman) -20.79
DHRM's Forward Rate of Return (Yacktman) is ranked lower than
83% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 1.19 vs. DHRM: -20.79 )
DHRM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -25.2   Max: -2.3
Current: -20.79

-25.2
-2.3

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:J8D.Germany
Dehaier Medical Systems Ltd., was incorporated in the British Virgin Islands in 2003 as a limited liability company. The Company is in the business of developing and distributing medical devices. It distributes products designed and manufactured by other companies. The Company broadens its product portfolio through distribution agreements with international manufacturers, and the products it distributes are imported. Its distribution offerings are mostly equipment used in the operating room, the intensive care unit ('ICU') and the emergency room. Besides distributing medical devices, it also design, develop and market its own proprietary products and medical components. Because it does not run any manufacturing facilities, it contracts some of the medical components to outside manufacturers in China. Its proprietary products require light assembly by it before distribution. Its proprietary and distributed products include two major categories: medical devices (including supporting products); and sleep respiratory and oxygen therapy products (previously defined as respiratory and oxygen homecare products). Its medical devices proprietary and distributed products are mainly used in hospitals and clinics, while the sleep respiratory and oxygen therapy products are mainly for hospitals, sleep centers, at-home use by individual, emergency center, national defense and national disaster relief circumstances. It sells its products primarily through distributors, but it also makes direct sales to hospitals, clinics, government health bureaus, government organizations and individuals. It continue to further its market reach by introducing newer and more advanced product lines that address different end-user needs. Its competitors include publicly traded and privately held multinational companies, such as Respironics, Inc., ResMed Inc., and Covidien, as well as domestic Chinese companies such as Beijing Aoji, Beijing Ya'ao, Jiangsu Yuyue and Zhejiang Longfei. Its products are medical devices and are subject to regulatory controls governing medical devices. As a distributor of medical equipment and supplies it is subject to regulation and oversight by different levels of the food and drug administration in China, in particular the SFDA. It is also subject to other PRC government laws and regulations.
» More Articles for NAS:DHRM

Headlines

Articles On GuruFocus.com
6 Stocks Meeting Benjamin Graham's NCAV Criteria in 2013 Apr 02 2013 


More From Other Websites
Nasdaq stocks posting largest percentage increases Sep 23 2014
Dehaier to Begin Providing Sleep Respiratory Solutions for Hospitals Across China Aug 28 2014
Dehaier Announces the Results of 2014 Shareholder Annual Meeting Jul 30 2014
Dehaier Showcases New Sleep Respiratory Solutions at 5th Chinese Sleep Medicine Congress Jul 21 2014
Dehaier Medical to Hold Annual General Meeting on July 28, 2014 Jun 30 2014
Dehaier Attends 8th Biennial Chinese Sleep Research Society Conference Jun 25 2014
DEHAIER MEDICAL SYSTEMS LTD Financials Apr 05 2014
Dehaier Medical Systems' CEO Discusses Q4 2013 Results - Earnings Call Transcript Apr 01 2014
Dehaier Announces Closing of $6.7 Million Registered Direct .. Feb 28 2014
Dehaier Extends Exclusive Distribution Authorization withTim .. Feb 20 2014
Dehaier Announces Upcoming Road Show In February Feb 18 2014
DehaierReceives CFDA Approval for DHR998 Sleep Diagnostic De .. Jan 10 2014
Dehaier To Attend Sleep Apnea Seminar In Qingdao Dec 22 2013
Dehaier Announces the Results of 2013 Shareholder Annual Mee .. Dec 20 2013
Dehaier Medical Wins Medical Equipment Procurement Bid for Shanxi Province Project Dec 18 2013
Dehaier Medical Participates inZdravookhraneniye'2013 Health .. Dec 05 2013
Dehaier Medical Participates in2013 MEDICA Nov 26 2013
Dehaier Medical Wins Large-Scale Medical Equipment Procureme .. Nov 19 2013
Dehaier Medical announces 'improved' sleep diagnostics device Nov 07 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK